RxDoctor Payments Data

Audrey Keen, PA

Physician Assistant · Springfield, VANPI 1417252974

Payments from drug & device makers

$4,378in general payments, 2019–2025

Across 232 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$901
  • Pfizer$365
  • Amgen$295
  • Astellas Pharma US Inc$224
  • Globus Medical$173
  • plus $1K from 34 others

What the payments were for

  • Food & beverage$4,27898%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,378 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$90,691
Medicare patients
329
Services billed
2,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$26,588
MounjaroTirzepatide19$22,123
XareltoRivaroxaban23$21,657
JardianceEmpagliflozin12$21,540
MyrbetriqMirabegron13$13,016
Rivastigmine12$4,588
Memantine Hcl ErMemantine Hcl11$3,806
Atorvastatin Calcium152$1,425
Rosuvastatin Calcium62$1,295
Metformin Hcl26$1,054
Levothyroxine Sodium87$792
Metoprolol Succinate31$776
Albuterol Sulfate HfaAlbuterol Sulfate36$767
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16$760
Escitalopram Oxalate44$744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$901$26,58822 claims
Lilly USA, LLCMounjaro$57$22,12319 claims
Johnson & JohnsonXarelto$22$21,65723 claims
Boehringer IngelheimJardiance$82$21,54012 claims
Astellas Pharma US IncMyrbetriq$224$13,01613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$145$79287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Springfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →